ClinicalTrials.gg
CompletedNCT05389722Updated Apr 19, 2023

A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants

A Phase 1 interventional study of CC-92480 and Rifampin in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-19.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2022, 4 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the drug levels of CC-92480 after coadministration with rifampin and itraconazole and the drug levels of digoxin and rosuvastatin after coadministration with CC-92480 in healthy participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • CC-92480
  • Healthy Volunteer
  • Pharmacokinetic
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have a between 18 and 33 kg/m2 (inclusive)
  • Adult female of nonchildbearing potential or male, any race or ethnicity, and in good health as determined by the medical history, physical exam, vital signs, 12-lead , and clinical laboratory assessments

Exclusion criteria

Exclusion Criteria:

  • Any surgical or medical condition possibly affecting drug absorption, distribution, metabolism, and excretion
  • Any major surgery within 4 weeks of the first dose administration
  • History of drug abuse within 2 years of the first dose administration

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Part 1

    Drug: CC-92480 · Drug: Rifampin

  • Experimental
    Part 2

    Drug: CC-92480 · Drug: Itraconazole

  • Experimental
    Part 3

    Drug: CC-92480 · Drug: Digoxin · Drug: Rosuvastatin

Interventions

  • Specified dose on specified days

    Also known as: BMS-986348

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Up to 2 months

  2. Time of maximum observed plasma concentration (Tmax)

    Time frame: Up to 2 months

  3. Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T))

    Time frame: Up to 2 months

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 3 months

  2. Number of participants with physical examination findings

    Time frame: Up to 3 months

  3. Number of participants with vital sign abnormalities

    Time frame: Up to 3 months

  4. Number of participants with 12-lead electrocardiogram (ECG) abnormalities

    Time frame: Up to 3 months

  5. Number of participants with clinical laboratory abnormalities

    Time frame: Up to 3 months

07

Study locations

1 site
  • Covance Clinical Research Unit - Dallas
    Dallas, Texas 75247-4968, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Nov 2022, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2022
First posted
May 25, 2022
StartActual
Jun 9, 2022
Primary completionActual
Nov 12, 2022
CompletionActual
Nov 12, 2022
Last update
Apr 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05389722
Responsible party
Sponsor
First posted
May 25, 2022
Start date
Jun 9, 2022
Primary completion
Nov 12, 2022
Completion
Nov 12, 2022
Last update
Apr 19, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mezigdomide

Start the discussion